Pertuzumab is a recombinant humanized mAb binding to the extracellular dimerization domain II of HER2 to prevent the ligand-induced HER2 heterodimer formation and reduce the survival of tumor (Barthelemy et al., 2014). Here, ERBB2 is linked to neoplasm.